Ginkgo Bioworks Holdings (DNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has a cash flow conversion efficiency ratio of -0.110x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.36 Million) by net assets ($420.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ginkgo Bioworks Holdings market capitalisation for the company's overall valuation and market capitalisation.
Ginkgo Bioworks Holdings - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ginkgo Bioworks Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their cash flow conversion efficiency. See Ginkgo Bioworks Holdings cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kirloskar Industries Limited
NSE:KIRLOSIND
|
0.024x |
|
Konya Cimento Sanayi AS
IS:KONYA
|
-0.051x |
|
CN EVERBRIGHT WATER HD 1
F:BIU2
|
N/A |
|
Bel Fuse A Inc
NASDAQ:BELFA
|
0.057x |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
0.008x |
|
Nantong Chaoda Equipment Co.Ltd.
SHE:301186
|
0.046x |
|
Arhaus Inc
NASDAQ:ARHS
|
0.115x |
|
Lion Travel Service Co Ltd
TW:2731
|
0.143x |
Annual Cash Flow Conversion Efficiency for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025. View DNA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $508.59 Million | $-171.06 Million | -0.336x | +24.64% |
| 2024-12-31 | $716.06 Million | $-319.58 Million | -0.446x | -65.71% |
| 2023-12-31 | $1.10 Billion | $-295.50 Million | -0.269x | -85.42% |
| 2022-12-31 | $1.74 Billion | $-252.20 Million | -0.145x | +10.30% |
| 2021-12-31 | $1.57 Billion | $-253.82 Million | -0.162x | +43.96% |
| 2020-12-31 | $470.05 Million | $-135.83 Million | -0.289x | -224.70% |
| 2019-12-31 | $501.85 Million | $-44.66 Million | -0.089x | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more